Neurofilament L (NF-L) is one of four subunits that form NFs, which are type III intermediate filament proteins that enable axonal growth, maintain structure, and facilitate nerve conduction.1,2 NF-L is comprised of an N-terminal domain that regulates neurofilament assembly, a central α-helical rod region that mediates dimerization, and a glutamic acid-rich C-terminal tail that is subject to phosphorylation.1,3,2 It is abundantly expressed in myelinated axons in the central and peripheral nervous systems and localizes to the cytoplasm, where it associates with an NF-middle (NF-M) or -heavy (NF-H) subunit to form parallel coiled-coil heterodimers.3 These heterodimers then associate in an anti-parallel manner to form tetramers, which assemble into NFs. Cerebrospinal fluid (CSF) NF-L levels have been used as a marker of axonal injury in a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s disease, and Alzheimer’s disease.1 Mutations in NEFL, the gene encoding NF-L, have been found in patients with Charcot-Marie-Tooth disease type 2E (CMT2E), a neurological disease characterized by muscle weakness and atrophy.4 Cayman’s Neurofilament L (C-Term) Rabbit Monoclonal Antibody (Clone RM280) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.WARNING This product is not for human or veterinary use.
